

DISEASE BURDEN

In 2022, 39 million people globally were living with HIV and 1.3 million people became newly infected, most of which occurred in LMICs.

CLINICAL RELEVANCE

GS-1720 is a novel INSTI. Phase I studies in participants with HIV-1 have been completed. It was shown to be potent and suited for once-weekly oral dosing. It is likely to be studied in combination with GS-4182, a new oral lenacapavir prodrug with improved bioavailability.

INTELLECTUAL PROPERTY LANDSCAPE

Gilead primary patents applications on GS-1720 have been filed in about 47 LMICs with an expected expiry in 2042. Further secondary patent filings are to be expected.

GS-1720
 HIV
 TREATMENT
 Gilead

SERVICE DELIVERY ENABLERS

Assessment in progress

REGULATORY

Assessment in progress

MANUFACTURING

Assessment in progress

MARKET

Assessment in progress